ArticleFrontiers in oncology2022

Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study.

Niek A Peters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.